TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00365274
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg orally daily days 1 - 5
Study: NCT00365274
Drug: SGN-30
Normalized name: SGN-30
DrugBank: SGN-30 (DB05471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
Study: NCT00192023
Drug: atomoxetine 1.2 mg/kg/day
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atomoxetine 1.2 mg/kg/day QD, PO
Study: NCT00192023
Drug: atomoxetine 1.2-1.4 mg/kg/day
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
Study: NCT04074343
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04074343
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01114672
Drug: 50,000 Units Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50,000 Units oral ergocalciferol to be given once weekly
Study: NCT04457258
Drug: Gallium Ga 68 FAPi-46
Normalized name: Gallium Ga 68 FAPi-46
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01108757
Drug: Bactrim
Normalized name: Bactrim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bactrim DS BID for 3 days
Study: NCT00196534
Drug: Human Thrombin
Normalized name: Human Thrombin
DrugBank: Human thrombin (DB11571)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00196534
Drug: Bovine Thrombin
Normalized name: Bovine thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01085656
Drug: OXi4503
Normalized name: OXI4503
DrugBank: OXI-4503 (DB05143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent.
Study: NCT03064165
Drug: Sodium Chloride 9mg/mL
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT02198261
Drug: 5% minoxidil topical foam
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil topical foam
Study: NCT00322140
Drug: CDDO
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00525278
Drug: Levocetirizine dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02734186
Drug: Praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthelminthic
Study: NCT04016805
Drug: Ublituximab
Normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion
Study: NCT04016805
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis
Study: NCT04016805
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Bruton Tyrosine Kinase (BTK) inhibitor~* Tablet form, to taken orally on a daily basis
Study: NCT04016805
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * BCL-2 inhibitor~* Tablet form, to be taken orally
Study: NCT04016805
Drug: Acalabrutinib Oral Capsule
Normalized name: acalabrutinib Oral Capsule
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinase inhibitor, capsule form, to be taken orally
Study: NCT00171795
Drug: Rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00788164
Drug: imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given topically
Study: NCT00251927
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg oral tablet administered daily
Study: NCT03770052
Drug: duvie
DrugBank: Lobeglitazone (DB09198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: take the intervention drug once daily according to the randomized groups
Study: NCT00829205
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00829205
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00829205
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00390455
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IM
Study: NCT00390455
Drug: Lapatinib Ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03885804
Drug: Quadratus lamborum dexmedetomidine intravenous
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
Study: NCT03447730
Drug: SYNB1020
Normalized name: SYNB1020
DrugBank: SYNB1020 (DB17667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB1020 was supplied at a concentration of approximately 1 × 10\^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
Study: NCT02023905
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus at 10 mg daily continuously
Study: NCT02023905
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
Study: NCT03324113
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution for eye drop~Route of administration: eye drop
Study: NCT03324113
Drug: naphazoline
Normalized name: Naphazoline
DrugBank: Naphazoline (DB06711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for eye drop~Route of administration: eye drop
Study: NCT03324113
Drug: diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03100864
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks treatment
Study: NCT01648036
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
Study: NCT01648036
Drug: Dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 5000 IU, subcutaneous, daily
Study: NCT02277197
Drug: Ficlatuzumab
Normalized name: Ficlatuzumab
DrugBank: Ficlatuzumab (DB11680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)
Study: NCT02277197
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended.
Study: NCT00362102
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02749136
Drug: Preoperative modified FOLFIRINOX and postoperative gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~  * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15
Study: NCT03039543
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
Study: NCT03039543
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
Study: NCT02583568
Drug: Bevacizumab-800CW
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: three days prior to surgery bevacizumab-800CW will be administered
Study: NCT00485056
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45mgs daily
Study: NCT02792647
Drug: IX-01
Normalized name: Hematoporphyrin ix
DrugBank: Hemoporfin (DB16183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00104637
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil citrate 25 mg by mouth thrice daily (po tid)
Study: NCT01313624
Drug: AZLI
Normalized name: Bazlitoran
DrugBank: Bazlitoran (DB14990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Study: NCT04510402
Drug: Povidine iodine nasal swabs
Normalized name: povidone-iodine Topical Ointment [Povidine]
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily versus twice daily nasal application
Study: NCT01598207
Drug: Marinol
Normalized name: Marinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg BID, orally for 1 month
Study: NCT01461824
Drug: Depot medroxyprogesterone acetate (DMPA)
Normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
Study: NCT01689766
Drug: Technetium Tc 99m EC20
Normalized name: TECHNETIUM (Tc 99m)
DrugBank: Technetium Tc-99m (DB14227)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00715013
Drug: Patupilone
Normalized name: Patupilone
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patupilone
Study: NCT02580240
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
Study: NCT03622541
Drug: Sorafenib 200mg
Normalized name: SORAFENIB 200MG TAB
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
Study: NCT04111523
Drug: SY-007
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of SY-007 or placebo injection(1mg-45mg)
Study: NCT02207439
Drug: Nelfinavir (Viracept®) 1250 mg
Normalized name: nelfinavir 250 MG [Viracept]
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
Study: NCT01832103
Drug: MK-7145
Normalized name: MK-7145
DrugBank: MK-7145 (DB11968)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00676156
Drug: oral lipoic acid (LA)
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 1200 mg dose of oral LA will be administered.
Study: NCT00676156
Drug: lipoic acid (LA) with fish oil and LA without fish oil
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
Study: NCT00676156
Drug: R lipoic acid
Normalized name: R-alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 1200mg R enantiomer LA will be administered.
Study: NCT00367341
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive treatment with escitalopram for 12 weeks.
Study: NCT03655665
Drug: Ofloxacin otic solution
Normalized name: ofloxacin Otic Solution
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
Study: NCT00984438
Drug: BCNU Wafer
Normalized name: carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implantable during surgical resection into the tumor bed
Study: NCT00984438
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV every 2 weeks for up to one year
Study: NCT00984438
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV every 2 weeks for up to one year
Study: NCT02420041
Drug: triamcinolone/lidocaine
Normalized name: triamcinolone/lidocaine 20 mg-20 mg/4 mL INJECTION VIAL (ML)
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01902498
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study: NCT01902498
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study: NCT01902498
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study: NCT03049345
Drug: Methylene Blue 20 MG/ML
Normalized name: methylene blue 20 MG/ML
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: see above
Study: NCT01278615
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03585686
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 20 mg/kg/day
Study: NCT03585686
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2/12 h, days 1-5
Study: NCT03585686
Drug: 2-chlorodeoxyadenosine
Normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/m2/d, days 1-5
Study: NCT02649361
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib p.o. qd
Study: NCT00616330
Drug: butoconazole nitrate
Normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: semi solid, single dose
Study: NCT03040830
Drug: Progesterone 100 IM/day
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
Study: NCT01073319
Drug: Rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
Study: NCT01073319
Drug: Rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
Study: NCT01906528
Drug: Mivacurium
Normalized name: Mivacurium
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effect of Mivacurium in males vs females
Study: NCT04054414
Drug: Normal Saline along with standard treatment
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
Study: NCT01900574
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
Study: NCT00715117
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
Study: NCT01240252
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
Study: NCT01652859
Drug: Liposomal Amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01652859
Drug: AmBisome
Normalized name: AmBisome
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00519285
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle
Study: NCT00519285
Drug: Placebo (for aflibercept)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle
Study: NCT00129740
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally twice daily
Study: NCT02312011
Drug: IONIS-DMPKRx
Normalized name: IONIS SOD1Rx
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT00081939
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.
Study: NCT00519285
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)
Study: NCT00119262
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00119262
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally